Nemolizumab

Summary

Nemolizumab (CHEMBL4297794) is an approved antibody (ATC D11AH12) targeting IL31RA; indicated across 5 conditions including prurigo and atopic eczema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: D11AH12
• Targets: 1 (IL31RA)
• Indications: 5 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297794
Name	Nemolizumab
Type	Antibody
Max phase	4
ATC	D11AH12

Also known as: CD14152, CIM-331, CIM331, Nemluvio, Nemolizumab, Nemolizumab-ilto, NEMOLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
IL31RA	Interleukin-31 receptor, α subunit	Binding	8.7	0.7%	Q8NI17

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): IL31RA.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
IL-6-type cytokine receptor ligand interactions	1	IL31RA

Dominant GO biological processes

GO term	Targets
MAPK cascade	1
glandular epithelial cell differentiation	1
acute inflammatory response to antigenic stimulus	1
defense response	1
cell surface receptor protein tyrosine kinase signaling pathway	1
cell surface receptor signaling pathway via JAK-STAT	1
positive regulation of cell population proliferation	1
cytokine-mediated signaling pathway	1
monocyte differentiation	1
macrophage differentiation	1
positive regulation of tyrosine phosphorylation of STAT protein	1
homeostatic process	1
negative regulation of macrophage activation	1
negative regulation of apoptotic process	1
positive regulation of DNA-templated transcription	1

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
prurigo	4	MONDO:0021739	MONDO:0021739
atopic eczema	3	MONDO:0004980	EFO:0000274
systemic sclerosis	2	MONDO:0005100	EFO:0000717
chronic kidney disease	1	MONDO:0005300	EFO:0003884

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE2	10
PHASE3	8
PHASE4	2
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07396168	PHASE4	RECRUITING	Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
NCT03989206	PHASE3	ACTIVE_NOT_RECRUITING	Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT04204616	PHASE3	ACTIVE_NOT_RECRUITING	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT03985943	PHASE3	COMPLETED	Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03989349	PHASE3	COMPLETED	Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT04501666	PHASE3	COMPLETED	Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04501679	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT05052983	PHASE3	COMPLETED	A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
NCT05056779	PHASE3	WITHDRAWN	Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
NCT05075408	PHASE2/PHASE3	COMPLETED	To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
NCT07047690	PHASE2	RECRUITING	A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07074977	PHASE2	RECRUITING	Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT01986933	PHASE2	COMPLETED	A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
NCT03100344	PHASE2	COMPLETED	Dose-ranging Study of Nemolizumab in Atopic Dermatitis
NCT03181503	PHASE2	COMPLETED	Safety and Efficacy of Nemolizumab in PN
NCT03921411	PHASE2	COMPLETED	A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
NCT04365387	PHASE2	COMPLETED	A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
NCT04562116	PHASE2	COMPLETED	A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345	PHASE2	COMPLETED	Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT05214794	PHASE2	COMPLETED	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
NCT05405985	PHASE1	COMPLETED	Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
NCT03358693	Not specified	RECRUITING	Molecular Signatures in Inflammatory Skin Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).